Login / Signup

Clinical significance of checkpoint regulator "Programmed death ligand-1 (PD-L1)" expression in meningioma: review of the current status.

Shirin KarimiSheila MansouriFarshad NassiriSevera BundaOlivia SinghPriscilla K BrastianosIan F DunnGelareh Zadeh
Published in: Journal of neuro-oncology (2021)
We conclude with a brief review of ongoing clinical trials using checkpoint inhibitors for the treatment of high-grade and refractory meningiomas.
Keyphrases
  • high grade
  • dna damage
  • clinical trial
  • current status
  • cell cycle
  • low grade
  • transcription factor
  • randomized controlled trial
  • cell proliferation
  • combination therapy
  • replacement therapy